Canaccord Genuity Maintains Buy on Nektar Therapeutics, Raises Price Target to $24

Canaccord Genuity maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $20 to $24.

Benzinga · 11/12/2019 13:12

Canaccord Genuity maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $20 to $24.